pharma · AUROPHARMA
Aurobindo Pharma
Aurobindo Pharma: PE above historical average. NARROW LEADERSHIP regime. sector leading.
Price
₹1,576.3
Price 2026-07-30
5 day
+2.89%
Short-term move
1 month
-0.15%
Medium-term
Regime
NARROW LEADERSHIP
62% confidence
Market cap
₹91.1k Cr
inflow sector flow
Market Intelligence Analyst
Understand today's market in about 2 minutes.
“How does today's NARROW LEADERSHIP regime affect Aurobindo Pharma (AUROPHARMA) in the pharma sector?”
Price chart
₹1,549
+38.72% over period
About Aurobindo Pharma
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin's, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
At a Glance
RSI pattern warning
RSI oversold bounces for this stock succeeded only 0% of the time (avg -10.2% over 14 days) — not a reliable pattern.
52-week position
Trading at 96.3% of 52-week high
Technicals
RSI 14
52.6
Trend
uptrend
50 DMA
Above
200 DMA
Above
Key metrics
P/E ratio
26.3
86th pct · 7 quarterly points (limited history)
P/B
2.4
ROE
9.9%
Below-average profitability — 9.9% ROE
Market cap
₹91.1k Cr
Revenue growth
560.0% YoY
Promoter
54.8%
52-week range
₹1,016.1 – ₹1,636.8
96.3% of high
RSI (14)
52.6
uptrend
vs 50 DMA
Above
DMA ₹1,515.07
Coverage
100/100
HIGH
Quick Take
Aurobindo Pharma: PE above historical average. NARROW LEADERSHIP regime. sector leading.
Peer comparison
| Stock | Price | 5D | P/E | ROE | Rev growth | Mcap |
|---|---|---|---|---|---|---|
| DIVISLAB Divi's Laboratories | ₹7,835 | +7.7% | 70 | 16.2% | 950% | ₹1.8L Cr |
| CIPLA Cipla | ₹1,466.4 | +5.3% | 30.2 | 11.7% | -210% | ₹1.2L Cr |
| DRREDDY Dr. Reddy's Laboratories | ₹1,144.8 | -1.8% | 26.5 | 11.8% | -1160% | ₹1.1L Cr |
| ALKEM Alkem Laboratories | ₹5,816.5 | +3.8% | 29.4 | 17.6% | 1460% | ₹67.8k Cr |
| BIOCON Biocon | ₹425.35 | -2.3% | 145.3 | 1.1% | 230% | ₹66.3k Cr |
| GLENMARK Glenmark Pharmaceuticals | ₹2,190.3 | -0.7% | 47 | 14.1% | 1430% | ₹63.9k Cr |
| GLAND Gland Pharma | ₹2,517 | +5.9% | 40.9 | 10.5% | 2230% | ₹42.1k Cr |
| JBCHEPHARM J B Chemicals | ₹2,408.9 | +0.0% | 54.5 | 18.7% | -480% | ₹38.9k Cr |
| AUROPHARMA Aurobindo Pharma | ₹1,576.3 | +3.5% | 26.3 | 9.9% | 560% | ₹91.1k Cr |
Tensions to watch
Promoter holding at 54.8% — neither distress selling nor aggressive buying
No strong insider signal. Watch for changes in promoter stake as a leading indicator.
Key Watchpoints
Breaks above ₹1655 (+5%)
Trend reversal confirmation
Breaks below ₹1497 (-5%)
Further downside risk
PE reverts to median of 20.6 (7 quarterly points (limited history))
Valuation normalization
Pharma sector holding leadership position
Sector momentum continuing
